drugset / Trial / NCT06632405
A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a phase II, explorative, open-labeled, multi-centered, double-arm, investigator-initiated clinical trial of Camrelizumab (an anti-PD-1 antibody) in combination with Nab-paclitaxel (a chemotherapeutic agent against breast cancer) and Levocetirizine (an antihistamine) in patients with advanced triple-negative breast cancer. 60 subjects will be enrolled in multiple centers. This study aims to evaluate the effects of Camrelizumab combined with Nab-paclitaxel and Levocetirizine in the treatment of advanced TNBC.
Timeline
- Start
- 2025-04-01
- Primary completion
- 2027-03-31
- Completion
- 2027-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Levocetirizine | Unknown | 5 mg | Oral |
| Background | Camrelizumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Background | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Background | Paclitaxel | Small molecule | 100 mg/m2 | Intravenous |